Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Practice Guidelines
    • Dermatology Guidelines
    • AIIMS guidance on...

    AIIMS guidance on antibiotic use in Skin and soft tissue infections

    Written by Dr. Kamal Kant Kohli Kohli Published On 2019-12-27T19:00:37+05:30  |  Updated On 27 Dec 2019 7:00 PM IST
    AIIMS guidance on antibiotic use in Skin and soft tissue infections
    All India Institute of Medical Sciences, Delhi has released AIIMS Antibiotics Policy which has been prepared by the Department of Medicine with Multidisciplinary collaboration. The guidance for antibiotic use in Skin and soft tissue infections includes Impetigo, Ecthyma Erysipelas the salient features of which are hereunder.

    Main recommendations:


    1.) Impetigo: Impetigo is a superficial infection of the skin. Starts with small vesicles that turn into pustules and ruptures readily. The purulent discharge dries and forms the characteristic golden yellow crusts. Pruritus is common and scratching of lesions results in spreading of infection. Healing generally occurs without scarring.


    2.) Ecthyma: It is an ulcerative form of impetigo with punched out edges.


    Treatment:


    A) Impetigo with numerous lesions, ecthyma or to control transmission during outbreaks, Bullous impetigo)- Staphylococcus aureus:


    Preferred: Amoxicillin-clavulanate 625mg TDS


    Alternative: Cephalexin 250-500 QID or Cefuroxime 250-500 mg BD


    If suspicion of MRSA:


    Preferred: Linezolid 600mg BD


    Alternative: Cotrimoxazole DS BD


    B) Non-bullous impetigo- fewer lesions- Group A Streptococcus (GAS)


    Preferred: Topical Mupirocin BD


    Alternative: Topical Fusidic acid QID


    Special Remarks:


    -Blood culture is not essential


    -Duration: 5-7 days


    3.) Erysipelas: This is a superficial infection of the skin, with prominent lymphatic involvement. It is a painful lesion with bright red, oedematous and indurated appearance. It has sharply demarcated borders. Presence of fever is a usual finding.


    Treatment:





    1. No systemic signs of toxicity- GAS:




    Preferred: Amoxicillin-clavulanate 625mg TDS for 5-7 days


    Alternative: Cephalexin 250-500 QID or Cefuroxime 250-500 mg BD for 5-7 days





    1. With signs of systemic toxicity/Rapid progression of symptoms despite 48 hours of oral- GAS:




    Preferred: Injection Ceftriaxone 1-2 g IV BD for 5 to 14 days


    Alternative: Clindamycin 600mg TDS for 5 to 14 days


    4.) Cellulitis: Acute spreading infection that involves subcutaneous tissue. Clinically rapidly intensifying pain and redness is a common presentation. Fever and lymphadenopathy may be present. The borders in cellulitis are not well demarcated.


    Treatment:





    1. Without signs of systemic toxicity- Staphylococcus aureus:




    -Tab Amoxicillin – clavulanate (625 mg) 1 tab TDS for 5 days


    -If MRSA suspected- Cotrimoxazole DS BD or Linezolid 600 mg BD





    1. With signs of systemic toxicity/Rapid progression of symptoms despite 48 hours of oral/proximity of the lesion to an indwelling medical device- Staphylococcus aureus:




    -Vancomycin (1g IV BD) or Teicoplanin (400 mg IV 12th hourly for three doses followed by 24th hourly) or Linezolid (600 mg BD) or Daptomycin (6 mg/kg OD) for 5-14 days


    5.) Necrotic soft tissue infection: Erythema/oedema/warmth with signs of systemic illness (fever, hemodynamic instability) and a) crepitus/skin discolouration/ foul-smelling discharge b) rapid progression of clinical symptoms c) Severe pain out of proportion.





    1. Necrotising fasciitis: Rapidly spreading infection located in the fascial planes of connective tissue that results in tissue necrosis. It can affect any part of the body but is most common in the lower limb. Abdominal wall, perianal/ groin areas and postoperative wounds are the other areas that are usually affected. The affected area is erythematous, swollen without sharp margins, hot, and painful in the early stage. Within3 to 5 days after onset, skin starts breaking down developing into bullae and subsequently cutaneous gangrene.




    2. Gas gangrene: It is a rapidly progressive life-threatening myonecrosis. It presents as a foul-smelling serosanguinous discharge from the wound. Crepitus is usually present. The area later turns into greenish-black cutaneous necrosis. Gram stain usually shows gram-positive bacilli with/ without spores. Anaerobic culture turns positive in as early as 6 hours’ time, with the growth as fast as the clinical progress. Imaging of the area may show evidence of gas in muscles and fascial planes.




    Treatment:


    Carbapenem (Imipenem 500 mg QID/Meropenem 1g TDS)/ BL-BLI inhibitor (Piperacillin-tazobactam 4.5 g QID/Cefoperazone sulbactam 3g BD)


    Plus, MRSA coverage (Vancomycin/ Teicoplanin/ Linezolid) Plus Clindamycin (600-900 mg IV TDS)- anti-toxin activity


    Urgent surgical debridement


    All India Institute of Medical Sciencesantibiotic useSkin and soft-tissue infections
    Source : All India Institute of Medical Sciences

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Dr. Kamal Kant Kohli Kohli
    Dr. Kamal Kant Kohli Kohli
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok